Secondary Logo

Most Popular Articles

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer

Owens, Gemma L.; Sheard, Victoria E.; Kalaitsidou, Milena; More

Journal of Immunotherapy. 41(3):130-140, April 2018.

Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy

Liu, Yanfen; Chen, Xinfeng; Wang, Dao; More

Journal of Immunotherapy. 41(9):406-410, November/December 2018.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Fischer, Jeannette; Paret, Claudia; El Malki, Khalifa; More

Journal of Immunotherapy. 40(5):187-195, June 2017.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Lindenberg, Melanie A.; Retèl, Valesca P.; van den Berg, Joost H.; More

Journal of Immunotherapy. 41(9):413-425, November/December 2018.

A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

Hoos, Axel; Parmiani, Giorgio; Hege, Kristen; More

Journal of Immunotherapy. 30(1):1-15, January 2007.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient

Pollack, Seth M.; Lu, Hailing; Gnjatic, Sacha; More

Journal of Immunotherapy. 40(8):302-306, October 2017.

Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy

Keilholz, Ulrich; Weber, Jeffrey; Finke, James H.; More

Journal of Immunotherapy. 25(2):97-138, March-April 2002.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products

Nowicki, Theodore S.; Escuin-Ordinas, Helena; Avramis, Earl; More

Journal of Immunotherapy. 41(5):248-259, June 2018.

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells

Merz, Christian; Sykora, Jaromir; Marschall, Viola; More

Journal of Immunotherapy. 41(9):385-398, November/December 2018.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial

Cohn, Allen; Morse, Michael A.; O’Neil, Bert; More

Journal of Immunotherapy. 41(3):141-150, April 2018.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

Tavera, René J.; Forget, Marie-Andrée; Kim, Young Uk; More

Journal of Immunotherapy. 41(9):399-405, November/December 2018.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Gangadhar, Tara C.; Hwu, Wen-Jen; Postow, Michael A.; More

Journal of Immunotherapy. 40(9):334-340, November/December 2017.

Dendritic Cells (DCs) Can Be Successfully Generated From Leukemic Blasts in Individual Patients With AML or MDS: An Evaluation of Different Methods

Kremser, Andreas; Dreyig, Julia; Grabrucker, Christine; More

Journal of Immunotherapy. 33(2):185-199, February-March 2010.

Cancer and Inflammation: Promise for Biologic Therapy

Demaria, Sandra; Pikarsky, Eli; Karin, Michael; More

Journal of Immunotherapy. 33(4):335-351, May 2010.

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection

Chandra, Janin; Dutton, Julie L.; Li, Bo; More

Journal of Immunotherapy. 40(2):62-70, February/March 2017.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients

Boudewijns, Steve; Westdorp, Harm; Koornstra, Rutger H.T.; More

Journal of Immunotherapy. 39(6):241-248, July/August 2016.

Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer

Scholl, Susy M.; Balloul, Jean-Marc; Le Goc, Gwenaelle; More

Journal of Immunotherapy. 23(5):570-580, September-October 2000.

Precision Cancer Immunotherapy: Optimizing Dendritic Cell-based Strategies to Induce Tumor Antigen-specific T-cell Responses Against Individual Patient Tumors

Osada, Takuya; Nagaoka, Koji; Takahara, Masashi; More

Journal of Immunotherapy. 38(4):155-164, May 2015.

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

Fotin-Mleczek, Mariola; Duchardt, Katharina M.; Lorenz, Christina; More

Journal of Immunotherapy. 34(1):1-15, January 2011.

Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy

Odegard, Jared M.; Kelley-Clarke, Brenna; Tareen, Semih U.; More

Journal of Immunotherapy. 38(2):41-53, February/March 2015.

In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status

Turin, Ilaria; Delfanti, Sara; Ferulli, Federica; More

Journal of Immunotherapy. 41(4):190-200, May 2018.

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

Dulos, John; Carven, Gregory J.; van Boxtel, Susan J.; More

Journal of Immunotherapy. 35(2):169-178, February-March 2012.

The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro

Dupuis, Maria L.; Fiori, Valentina; Soriani, Alessandra; More

Journal of Immunotherapy. 38(9):357-370, November/December 2015.

A Randomized Controlled Study of Immunochemotherapy with OK-432 after Curative Surgery for Gastric Cancer

Sato, Yuji; Kondo, Masao; Kohashi, Shigechika; More

Journal of Immunotherapy. 27(5):394-397, September-October 2004.

Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer

Fujiwara, Shinichi; Wada, Hisashi; Miyata, Hiroshi; More

Journal of Immunotherapy. 35(6):513-521, July-August 2012.

The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease

Bollard, Catherine M.; Straathof, Karin C. M.; Huls, M. Helen; More

Journal of Immunotherapy. 27(4):317-327, July/August 2004.

Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release

Amann, Maria; dÁrgouges, Sandrine; Lorenczewski, Grit; More

Journal of Immunotherapy. 32(5):452-464, June 2009.

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

Butterfield, Lisa H.; Comin-Anduix, Begonya; Vujanovic, Lazar; More

Journal of Immunotherapy. 31(3):294-309, April 2008.

Constitutively Active STAT5b Induces Cytokine-Independent Growth of the Acute Myeloid Leukemia–Derived MUTZ-3 Cell Line and Accelerates Its Differentiation Into Mature Dendritic Cells

Bontkes, Hetty J.; Ruizendaal, Janneke J.; Kramer, Duco; More

Journal of Immunotherapy. 29(2):188-200, March-April 2006.

Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells

Hammond, Caitlin; Shi, Yonghong; Mena, Jenny; More

Journal of Immunotherapy. 28(1):28-39, January-February 2005.

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

Monk, Paul; Lam, Elaine; Mortazavi, Amir; More

Journal of Immunotherapy. 37(3):180-186, April 2014.